Physician profile
Usama Bin Nasir
NPI 1134570633
$3,292.81
in general payments reported to CMS, 2019-2025
22 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $472 · 2023: $1,153 · 2024: $736 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.15 |
| Education | $297.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $644.03 | 2022-2025 | Ensite, Cardiomems, Jot Dx |
| Novartis Pharmaceuticals Corporation | $423.67 | 2023-2025 | |
| Amgen INC. | $356.54 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $340.79 | 2022-2024 | Watchman Access System |
| Heartflow, INC. | $197.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.40 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $171.07 | 2024-2025 | Corevalve Evolut R, Linq II |
| Pfizer INC. | $122.38 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $119.07 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $103.47 | 2022-2023 | Farxiga |
| Novo Nordisk INC | $102.22 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $101.39 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $82.37 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.85 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.88 | 2023 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $47.18 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $32.44 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $31.49 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $29.03 | 2025 | |
| Sanofi-Aventis U.S. LLC | $28.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.77 | 2022 | |
| Merck Sharp & Dohme LLC | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usama Bin Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.